Enliven Therapeutics, Inc. Stock Analysis & AI Score
Enliven Therapeutics, Inc. (ELVN) has an ST Score of 63.9 (B), driven by its Financial Strength (A+) and held back by its Growth (C-). Analysts rate it Buy with a $76.29 price target (+84.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIELVN Stock Price History
ELVN Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
ELVN Latest Stock News
ST Score
Enliven Therapeutics, Inc. (ELVN) has an ST Score of 63.9 (B), driven by its Financial Strength (A+) and held back by its Growth (C-). Analysts rate it Buy with a $76.29 price target (+84.9% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthC-
All factor grades
- Financial StrengthA+
- ProfitabilityA
- ValuationA-
- MomentumB+
- ForecastB+
- GrowthC-
- Piotroski2/9
Press Releases
Company Contact Details
ELVN stock: frequently asked questions
What is ELVN's ST Score?
Enliven Therapeutics, Inc. (ELVN) has an ST Score of 63.9 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ELVN a buy, hold, or sell?
Analysts rate ELVN a Buy, with a price target of $76.29 (+84.9% vs the current price). Our ST Score grades it B (63.9/100). The ST Score is a data-driven signal, not a recommendation.
What are ELVN's factor grades?
Valuation A-, Profitability A, Financial Strength A+, Momentum B+, Growth C-, Forecast B+.
What is ELVN's valuation grade?
Enliven Therapeutics, Inc. (ELVN) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ELVN's growth grade?
Enliven Therapeutics, Inc. (ELVN) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ELVN's profitability grade?
Enliven Therapeutics, Inc. (ELVN) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ELVN's financial strength grade?
Enliven Therapeutics, Inc. (ELVN) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ELVN?
The average analyst price target for Enliven Therapeutics, Inc. (ELVN) is $76.29 from 9 analysts, which is +84.9% versus the recent price of $41.25.
What is ELVN's Piotroski score?
Enliven Therapeutics, Inc. (ELVN) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.